Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections (DoSe iT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04016051
Recruitment Status : Completed
First Posted : July 11, 2019
Last Update Posted : July 11, 2019
Sponsor:
Information provided by (Responsible Party):
Grünenthal GmbH

Brief Summary:
This study was performed in children with upper respiratory tract infections (acute ear infection, infection of the tonsils or throat, or bacterial inflammation of the bronchi) who needed treatment with an antibiotic (clarithromycin). The study investigated a new technology which delivers the antibiotic in a straw (dose sipping technology, DST) in comparison to a marketed syrup.

Condition or disease Intervention/treatment Phase
Otitis Media Tonsillitis Pharyngitis Bronchitis Drug: Clarithromycin DST (125 mg) Drug: Clarithromycin DST (187.5 mg) Drug: Clarithromycin DST (250 mg) Drug: Clarithromycin Syrup (125 mg) Drug: Clarithromycin Syrup (187.5 mg) Drug: Clarithromycin Syrup (250 mg) Phase 3

Detailed Description:

The study population were children aged 2-12 years (weight 12-40 kg) suffering from upper respiratory tract infections (acute otitis media, tonsillitis, pharyngitis, or acute bacterial bronchitis) and who needed antibiotic treatment. The study compared treatment satisfaction and treatment adherence of oral clarithromycin DST (125 mg, 187.5 mg, or 250 mg twice daily) with the established oral clarithromycin syrup administered via a graduated syringe (Klacid Syrup Forte®, 250 mg/5mL) at the same fixed daily doses.

Fixed doses of 125 mg, 187.5 mg and 250 mg of clarithromycin DST offer the pediatrician the flexibility to treat children of different body weight and age adequately at the recommended daily dose of 15 (12.5-20) mg/kg. All children were treated for 7 to 10 day (14 to 20 doses). Treatment satisfaction by the guardian/caregiver in terms of handling and administration of the clarithromycin DST straw and the comparator clarithromycin syrup, convenience of the administration, acceptance of taste and aftertaste, and treatment satisfaction with respect to future use was evaluated by means of a Parents' Questionnaire once on either Day 3, 4, or 5 and once on either Day 11, 12, 13, or 14. In addition, treatment adherence/willingness of medication intake and the child's health status were assessed. The safety program comprised recording and evaluation of adverse events and countermeasures.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 265 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Treatment Satisfaction and Treatment Adherence of a Novel Application Form "Dose Sipping Technology" (DST) of Oral Clarithromycin vs. Clarithromycin Syrup in Children Suffering From Acute Otitis Media, Tonsillitis, Pharyngitis, or Acute Bacterial Bronchitis (DoSe iT)
Actual Study Start Date : September 22, 2004
Actual Primary Completion Date : December 23, 2004
Actual Study Completion Date : December 23, 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tonsillitis

Arm Intervention/treatment
Experimental: Clarithromycin DST

Participants received oral administration of Clarithromycin DST twice a day:

  • 125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).
  • 187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).
  • 250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).

For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw.

Drug: Clarithromycin DST (125 mg)
Clarithromycin DST (125.0 mg clarithromycin / straw).

Drug: Clarithromycin DST (187.5 mg)
Clarithromycin DST (187.5 mg clarithromycin / straw).

Drug: Clarithromycin DST (250 mg)
Clarithromycin DST (250.0 mg clarithromycin / straw).

Active Comparator: Clarithromycin Syrup

Participants received oral administration of Clarithromycin Syrup twice a day:

  • 2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).
  • 3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).
  • 5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years).
Drug: Clarithromycin Syrup (125 mg)
Clarithromycin Syrup 2.5 ml (125 mg).
Other Name: Klacid Syrup® Forte 250 mg/5mL

Drug: Clarithromycin Syrup (187.5 mg)
Clarithromycin Syrup 3.75 ml (187.5 mg).
Other Name: Klacid Syrup® Forte 250 mg/5mL

Drug: Clarithromycin Syrup (250 mg)
Clarithromycin Syrup 5 ml (250 mg).
Other Name: Klacid Syrup® Forte 250 mg/5mL




Primary Outcome Measures :
  1. Preparation of the medication (during treatment) [ Time Frame: Day 3-5 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How was the preparation of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.

  2. Preparation of the medication (after treatment) [ Time Frame: Day 11-14 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How was the preparation of the medication?". Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.

  3. Dosing accuracy (during treatment) [ Time Frame: Day 3-5 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How do you rate giving the right dose?". Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "difficult" and "very difficult". The best outcome was "very simple", the worst "very difficult". The percentage of responses for each of the possible answers was calculated.

  4. Dosing accuracy (after treatment) [ Time Frame: Day 11-14 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How do you rate giving the right dose?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "difficult" and "very difficult". The best outcome was "very simple", the worst "very difficult". The percentage of responses for each of the possible answers was calculated.

  5. Handling of the medication (during treatment) [ Time Frame: Day 3-5 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How satisfied are you with the handling of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very satisfied", "satisfied", "less satisfied" and "not satisfied". The best outcome was "very satisfied", the worst "not satisfied". The percentage of responses for each of the possible answers was calculated.

  6. Handling of the medication (after treatment) [ Time Frame: Day 11-14 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How satisfied are you with the handling of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very satisfied", "satisfied", "less satisfied" and "not satisfied". The best outcome was "very satisfied", the worst "not satisfied". The percentage of responses for each of the possible answers was calculated.

  7. Administration of the medication (during treatment) [ Time Frame: Day 3-5 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How do you judge the administration of the medication?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.

  8. Administration of the medication (after treatment) [ Time Frame: Day 11-14 ]

    This was analyzed by a Parents' Questionnaire by means of the question "How do you judge the administration of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14.

    Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.


  9. Ease to follow the prescribed dosing schedule (during treatment) [ Time Frame: Day 3-5 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How easy is it to follow the dosing schedule?" Parents were asked to respond once on either Day 3, 4, or 5. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.

  10. Ease to follow the prescribed dosing schedule (after treatment) [ Time Frame: Day 11-14 ]
    This was analyzed by a Parents' Questionnaire by means of the question "How easy is it to follow the dosing schedule?" Parents were asked to respond once on either Day 11, 12, 13, or 14. Possible answers (tick one only) were "very simple", "simple", "complicated" and "very complicated". The best outcome was "very simple", the worst "very complicated". The percentage of responses for each of the possible answers was calculated.

  11. Child's feeling about the taste of the medication (during treatment) [ Time Frame: Day 3-5 ]

    This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the taste of the medication?".

    Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.


  12. Child's feeling about the taste of the medication (after treatment) [ Time Frame: Day 11-14 ]

    This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the taste of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14.

    Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.


  13. Child's feeling about aftertaste of the medication (during treatment) [ Time Frame: Day 3-5 ]

    This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the aftertaste of the medication?" Parents were asked to respond once on either Day 3, 4, or 5.

    Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.


  14. Child's feeling about the aftertaste of the medication (after treatment) [ Time Frame: Day 11-14 ]

    This was analyzed by a Parents' Questionnaire by means of the question "What does your child feel about the aftertaste of the medication?" Parents were asked to respond once on either Day 11, 12, 13, or 14.

    Possible answers (tick one only) were "very good", "good", "acceptable", "bad", "very bad" and "no comment". The best outcome was "very good", the worst "very bad". The percentage of responses for each of the possible answers was calculated.


  15. Optimal administration form [ Time Frame: Day 11-14 ]

    This was analyzed by a Parents' Questionnaire by means of the question "Do you think the administration form is optimal for your child?". Parents were asked to respond once on either Day 11, 12, 13, or 14.

    Possible answers (tick one only) were "Yes", "No", and "Do not know". The percentage of responses for each of the possible answers was calculated.


  16. Treatment preference [ Time Frame: Day 11-14 ]

    Treatment preference was analyzed by a Parents' Questionnaire by means of the question "Would you or your child prefer this administration form next time?" Parents were asked to respond once on either Day 11, 12, 13, or 14.

    Possible answers (tick one only) were "Yes" and "No". The percentage of responses for each of the possible answers was calculated.


  17. Treatment adherence [ Time Frame: Day 11-14 ]

    The child's adherence to the prescribed course of therapy was checked by determining the number of unused straws or the residual volume in the medication bottles, respectively, when unused study medication was returned to the site on Day 11, 12, 13, or 14. A participant was considered to be:

    • Fully treatment adherent: >90 % of prescribed doses taken within the prescribed course of therapy.
    • Partially treatment adherent: 70-90% of prescribed doses taken within the prescribed course of therapy.
    • Non adherent: Omission of 2 or more consecutive doses or <70% of prescribed doses taken within the prescribed course of therapy.

    The percentage of participants in each of the 3 categories was calculated.



Secondary Outcome Measures :
  1. Child's Health Status compared to Baseline (during treatment) [ Time Frame: Day 3-5 ]
    The participant's overall health status compared to baseline (= acute infection requiring antibiotic treatment) was assessed by the investigator as "cured", "improved", "no changes", or "deteriorated". The clinical assessment was made during a phone interview with the parent/caregiver on either Day 3, 4, or 5. The best outcome was "cured", the worst was "deteriorated". The percentage of participants per outcome category was calculated.

  2. Child's Health Status compared to Baseline (after treatment) [ Time Frame: Day 11-14 ]
    The participant's overall health status compared to baseline (= acute infection requiring antibiotic treatment) was assessed by the investigator as "cured", "improved", "no changes", or "deteriorated". The clinical assessment was made once at a site visit on either Day 11, 12, 13. or 14. The best outcome was "cured", the worst was "deteriorated". The percentage of participants per outcome category was calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female children weighing 12-40 kg.
  • Age 2 -12 years.
  • Written informed consent (parents).
  • Diagnosis of acute otitis media, tonsillitis, pharyngitis, or acute bacterial bronchitis requiring antibiotic treatment.

Exclusion Criteria:

  • Participation in another study of investigational products or of devices parallel to, or less than 4 weeks before study entry, or previous participation in this study (for safety reasons).
  • Known to or suspected of not being able to comply with the study protocol and the use of clarithromycin.
  • Requirement for, or current use of, systemic antibacterial agents not specified in the protocol.
  • Necessity of dose reduction due to any concomitant disease.
  • Known human immunodeficiency virus (HIV) positive.
  • Other inflammatory/infectious diseases of the ear, the upper respiratory tract or the nose and throat.
  • History or presence of disease or concomitant medication contraindicating the use of clarithromycin.
  • Known or suspected intolerance / hypersensitivity to macrolides.
  • Contraindications according to the clarithromycin Summary of Product Characteristics (SmPC).
  • Indication for antibiotic treatment for less than 7 days or more than 10 days.
  • If known before entry, bacterial isolate resistant to clarithromycin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04016051


Locations
Layout table for location information
Germany
DE11
Balve, Germany, 58802
DE10
Beckum, Germany, 59269
DE09
Hameln, Germany, 31785
DE08
Hannover, Germany, 30625
DE12
Künzing, Germany, 94550
DE14
München, Germany, 80393
DE05
München, Germany, 81241
DE06
München, Germany, 81543
DE03
München, Germany, 81669
DE02
München, Germany, 81675
DE13
München, Germany, 81739
DE04
Olching, Germany, 82140
DE07
Pullach im Isartal, Germany, 82049
DE01
Unterhaching, Germany, 82008
Poland
PL03
Kozieglowy, Poland
PL06
Kraków, Poland
PL01
Lódz, Poland
PL04
Otwock, Poland
PL05
Warszawa, Poland
PL02
Wroclaw, Poland
Sponsors and Collaborators
Grünenthal GmbH
Investigators
Layout table for investigator information
Study Director: Grünenthal Study Director Grünenthal GmbH

Layout table for additonal information
Responsible Party: Grünenthal GmbH
ClinicalTrials.gov Identifier: NCT04016051     History of Changes
Other Study ID Numbers: KF-DSTCLA/01
First Posted: July 11, 2019    Key Record Dates
Last Update Posted: July 11, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Clarithromycin
Pharyngitis
Tonsillitis
Bronchitis
Otitis
Otitis Media
Ear Diseases
Otorhinolaryngologic Diseases
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Pharyngeal Diseases
Stomatognathic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors